In this context, the development of the inhibitors of sodium/glucose cotransporters 2 (SGLT2i) represents a major step forward in the research of novel nephroprotective agents for diabetic CKD, and, possibly, for non-diabetic CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.